Over 100 letters have been issued by the FDA regarding Direct-to-Consumer (DTC) practices. Join us as we digest and summarize these letters, address what is driving the proposed changes by the FDA, understand the internal pressures on Pharma and Biotech leadership and regulatory teams, and the impact to marketers and patient communities.
During this panel presentation, we will:
- Clarify the issues facing current DTC approaches
- Explore recent FDA enforcement trends
- Discuss the implications for biopharma marketing/commercial approaches and changes that need to take place with the current approaches
- Highlight the potential wholesale shifts that may impact creative approaches, channel mix and the overall approach to DTC and brand communications.
- Share potential strategic corporate responses and contingency planning if DTC advertising faces severe restrictions or ultimately banned
This webinar will focus on the challenges and potential changes to Direct-to-Consumer (DTC) advertising in the US and is designed for commercial leaders, brand marketers, clinical and regulatory pharma and biotech, media and engagements specialists, and patient advocates.
Moderator:
- Michael Parisi, Chief Client Officer, Lumanity
- Panelists:
- Jackie Singley, Head of Engagement, Lumanity
- Brigid DeCoursey Bondoc, Partner, Morrison Foerster
- Lee Maniscalco, Board Member, Strategic Advisor, and former CEO, Haymarket Media
- Christine Verini, CEO, CancerCare
